Immuneering Corporation Announces Grant of Inducement Award
21 mars 2025 16h30 HE
|
Immuneering Corporation
Immuneering Corporation Announces Grant of Inducement Award
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
20 mars 2025 16h05 HE
|
Immuneering Corporation
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
20 mars 2025 07h00 HE
|
Immuneering Corporation
IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer
17 mars 2025 09h00 HE
|
PEP-Therapy
Press release PEP-Therapy receives FDA Orphan Drug Designation for PEP-010for treatment of Pancreatic Cancer Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company...
Amplified Sciences earns CLIA certification for its first test to assess pancreatic cancer risk
19 févr. 2025 09h01 HE
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amplified Sciences, a clinical-stage life sciences diagnostic company that develops tests for early, more accurate detection of challenging...
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
11 févr. 2025 08h45 HE
|
AIM ImmunoTech Inc.
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod)...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
06 févr. 2025 07h00 HE
|
Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
05 févr. 2025 08h00 HE
|
AIM ImmunoTech Inc.
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
03 févr. 2025 16h05 HE
|
Immuneering Corporation
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
22 janv. 2025 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of...